These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 23437092)

  • 1. Similar trends in serum VEGF-D levels and kidney angiomyolipoma responses with longer duration sirolimus treatment in adults with tuberous sclerosis.
    Malinowska IA; Lee N; Kumar V; Thiele EA; Franz DN; Ashwal S; Sagalowsky A; Dimario FJ; Cutler D; Krueger D; Camposano S; Paolini J; Dabora SL
    PLoS One; 2013; 8(2):e56199. PubMed ID: 23437092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease.
    Dabora SL; Franz DN; Ashwal S; Sagalowsky A; DiMario FJ; Miles D; Cutler D; Krueger D; Uppot RN; Rabenou R; Camposano S; Paolini J; Fennessy F; Lee N; Woodrum C; Manola J; Garber J; Thiele EA
    PLoS One; 2011; 6(9):e23379. PubMed ID: 21915260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CT characteristics predict the response to everolimus or sirolimus of renal angiomyolipomas in patients with tuberous sclerosis complex.
    Wang W; Guo H; Shi B; Sun H; Li H; Zhang Y; Cai Y
    Int Urol Nephrol; 2019 Apr; 51(4):671-676. PubMed ID: 30756282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.
    Bissler JJ; McCormack FX; Young LR; Elwing JM; Chuck G; Leonard JM; Schmithorst VJ; Laor T; Brody AS; Bean J; Salisbury S; Franz DN
    N Engl J Med; 2008 Jan; 358(2):140-51. PubMed ID: 18184959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis.
    Budde K; Zonnenberg BA; Frost M; Cheung W; Urva S; Brechenmacher T; Stein K; Chen D; Kingswood JC; Bissler JJ
    Br J Clin Pharmacol; 2016 May; 81(5):958-70. PubMed ID: 26580489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial.
    Davies DM; de Vries PJ; Johnson SR; McCartney DL; Cox JA; Serra AL; Watson PC; Howe CJ; Doyle T; Pointon K; Cross JJ; Tattersfield AE; Kingswood JC; Sampson JR
    Clin Cancer Res; 2011 Jun; 17(12):4071-81. PubMed ID: 21525172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for pericyte origin of TSC-associated renal angiomyolipomas and implications for angiotensin receptor inhibition therapy.
    Siroky BJ; Yin H; Dixon BP; Reichert RJ; Hellmann AR; Ramkumar T; Tsuchihashi Z; Bunni M; Dillon J; Bell PD; Sampson JR; Bissler JJ
    Am J Physiol Renal Physiol; 2014 Sep; 307(5):F560-70. PubMed ID: 24920756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of serum vascular endothelial growth factor-D concentration with clinical presentation and course of lymphangioleiomyomatosis.
    Radzikowska E; Jaguś P; Sobiecka M; Chorostowska-Wynimko J; Wiatr E; Kuś J; Roszkowski-Śliż K
    Respir Med; 2015 Nov; 109(11):1469-75. PubMed ID: 26386638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sirolimus can promote the disappearance of renal angiomyolipoma associated with tuberous sclerosis complex: a prospective cohort study.
    Dun S; Wang YY; Wan L; Wang QH; Lu Q; Yang XY; Zhang Q; Chen HM; Qiu LP; Zou LP
    World J Pediatr; 2024 Jun; 20(6):602-610. PubMed ID: 37773307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis.
    Bissler JJ; Nonomura N; Budde K; Zonnenberg BA; Fischereder M; Voi M; Louveau AL; Herbst F; Bebin EM; Curatolo P; Zonta A; Belousova E
    PLoS One; 2018; 13(9):e0201005. PubMed ID: 30192751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus versus sirolimus for angiomyolipoma associated with tuberous sclerosis complex: a multi-institutional retrospective study in China.
    Luo C; Zhang YS; Zhang MX; Chen MF; Li Y; Qi L; Li HZ; Zu XB; Cai Y
    Orphanet J Rare Dis; 2021 Jul; 16(1):299. PubMed ID: 34217357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1.
    Kingswood JC; Jozwiak S; Belousova ED; Frost MD; Kuperman RA; Bebin EM; Korf BR; Flamini JR; Kohrman MH; Sparagana SP; Wu JY; Brechenmacher T; Stein K; Berkowitz N; Bissler JJ; Franz DN
    Nephrol Dial Transplant; 2014 Jun; 29(6):1203-10. PubMed ID: 24729041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial.
    Bissler JJ; Kingswood JC; Radzikowska E; Zonnenberg BA; Frost M; Belousova E; Sauter M; Nonomura N; Brakemeier S; de Vries PJ; Berkowitz N; Miao S; Segal S; Peyrard S; Budde K
    Nephrol Dial Transplant; 2016 Jan; 31(1):111-9. PubMed ID: 26156073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microscopic Kidney Disease in Tuberous Sclerosis Complex and Treatment With mTOR Inhibition.
    Kronick J; Gabril MY; House AA
    Am J Kidney Dis; 2023 Dec; 82(6):772-775. PubMed ID: 37532078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Rapamycin in the treatment of renal diseases associated with tuberous sclerosis complex].
    Dun S; Zou LP; Zhang MN; Wang YY; He W; Chen HM; Hu LY; Chen XQ; Lu Q; Pang LY; Liu LY; Tang LN; Wang B
    Zhonghua Er Ke Za Zhi; 2019 Nov; 57(11):852-856. PubMed ID: 31665839
    [No Abstract]   [Full Text] [Related]  

  • 16. The effect of sirolimus on angiomyolipoma is determined by decrease of fat-poor compartments and includes striking reduction of vascular structures.
    Watanabe EH; Coelho FMA; Filho HL; Balbo BEP; Neves PDMM; Franzin FM; Yamauchi FI; Onuchic LF
    Sci Rep; 2021 Apr; 11(1):8493. PubMed ID: 33875750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study.
    Su R; Huang T; Gu L; Bao Y; Liu Z; Dao P; Yao L; Hu X; Fu G; Wu J; Tricard T; Wu G; Chen M; Li C; Huang Z; Zheng B; Chen Y; Xue W; Guo G; Dong P; Huang J; Zhang J
    Cancer Med; 2024 Sep; 13(17):e70181. PubMed ID: 39279295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial.
    Cai Y; Guo H; Wang W; Li H; Sun H; Shi B; Zhang Y
    Orphanet J Rare Dis; 2018 Mar; 13(1):43. PubMed ID: 29587809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC).
    Brakemeier S; Vogt L; Adams L; Zukunft B; Diederichs G; Hamm B; Budde K; Makowski MR
    PLoS One; 2017; 12(12):e0189132. PubMed ID: 29232371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus and tuberous sclerosis-associated renal angiomyolipomas.
    Krischock L; Beach R; Taylor J
    Arch Dis Child; 2010 May; 95(5):391-2. PubMed ID: 20457704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.